Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
User Access and Controls

User Access and Controls

View Detailed Analysis

Analytics Overview

18
Form 483s Issued
2
483s converted to WL
18
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
21 Jun 2024
Cipla Limited
Drugs
22 Dec 2023
Eugia US Manufacturing LLC
Drugs
14 Nov 2023
Carma Laboratories, Inc.
Drugs
18 Oct 2023
NATCO Pharma Limited
Drugs
25 Aug 2023
Central Admixture Pharmacy Services Inc
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Nibin Varghese
3
0
Annet R Rajan
1
1
Arsen Karapetyan
1
0
Brian Janelsins, PhD
1
0
Andrew 'Drew' Haack, PhD
1
0
TITLE/ COMPANY Issue Date Status Details
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records
Cipla Limited
21 Jun 2024 Normal Justification: The observation points to inadequate control and assignment of user privileges, directly linking to User Access and Controls.
Excerpt: User privileges assigned within the manufacturing equipment used for products intended for the US market are not appropriate for the job functions being performed nor are they adequately defined.
View Details
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Eugia US Manufacturing LLC
22 Dec 2023 Normal Justification: The observation highlights weaknesses in user access management and the use of shared accounts, which are central to user access and control processes.
Excerpt: Your firm’s NetSCADA software used to operate (b) (4) all users have access to a non-specific administrator-level account.
View Details
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Carma Laboratories, Inc.
14 Nov 2023 Normal Justification: The enabled deletion function and unauthorized access suggests a breakdown in user access control procedures.
Excerpt: The delete functions are enabled in all your laboratory computer systems...
View Details
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
NATCO Pharma Limited
18 Oct 2023 Normal Justification: The observation specifically mentions unauthorized access by production operators and the lack of assigned user roles, indicating a fundamental issue with user access and controls.
Excerpt: Production Operator accessed this machine using user access. Further investigation indicated the equipment has fifteen listed users and the "Operator" access is not assigned to anyone of them.
View Details
Input to and output from the computer, related systems of formulas and records or data are not checked for accuracy.
Central Admixture Pharmacy Services Inc
25 Aug 2023 Normal Justification: The unauthorized use signifies a lapse in user access management controls during technician absences.
Excerpt: "I was on vacation and was locked out."
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.